Filtros de búsqueda

Lista de obras de

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

artículo científico publicado en 2007

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

artículo científico publicado en 2017

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Restaurantmanhaj's

artículo científico publicado en 2014

Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease

scientific article published on 01 May 2006

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report

scientific article published on 19 July 2018

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis

artículo científico publicado en 2010

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

artículo científico publicado en 2012

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda